These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6140695)

  • 21. Perazine and carbamazepine in comparison to olanzapine in schizophrenia.
    Ohlmeier MD; Jahn K; Wilhelm-Gossling C; Godecke-Koch T; Hoffmann J; Seifert J; Emrich HM; Schneider U
    Neuropsychobiology; 2007; 55(2):81-8. PubMed ID: 17570951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic dosage reduction in treatment-resistant schizophrenic patients.
    Van Putten T; Marshall BD; Liberman R; Mintz J; Kuehnel TG; Bowen L; Aravagiri M; Marder SR
    Psychopharmacol Bull; 1993; 29(2):315-20. PubMed ID: 7904763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suspension of neuroleptic therapy in acute schizophrenia.
    Kuhs H; Eikelmann B
    Pharmacopsychiatry; 1988 Jul; 21(4):197-202. PubMed ID: 2905064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
    Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
    Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy and tolerability of quetiapine in hospitalised schizophrenic patients during the acute treatment phase: a PMS study].
    Leweke FM; Gerth CW; Koethe D; Nolden BM; Klosterkötter J
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):211-9. PubMed ID: 17230308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bromocriptine in augmentation of antipsychotic response in chronic schizophrenia: a negative pilot report.
    Wells BG; Chu CC; Abi-Darghum A; Saini TS
    Pharmacopsychiatry; 1991 Jul; 24(4):118-20. PubMed ID: 1684441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
    Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
    J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
    Kopala LC; Fredrikson D; Good KP; Honer WG
    Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
    [No Abstract]   [Full Text] [Related]  

  • 31. Pipotiazine palmitate: an evaluation of a new long acting intramuscular antipsychotic agent in severely ill schizophrenic patients.
    Gallant DM; Mielke D; Bishop G; Oelsner T; Guerrero-Figueroa R
    Dis Nerv Syst; 1975 Apr; 36(4):193-6. PubMed ID: 1090427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can changes in eye-contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment? Results of a preliminary study.
    Meya U; Renfordt E
    Pharmacopsychiatry; 1986 Nov; 19(6):429-33. PubMed ID: 2879296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma protein binding of perazine and amitriptyline in psychiatric patients.
    Brinkschulte M; Gaertner HJ; Schied HW; Breyer-Pfaff U
    Eur J Clin Pharmacol; 1982; 22(4):367-73. PubMed ID: 6125396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The outpatient clinic for patients under chronic lithium or neuroleptic treatment as a phase-IV research tool.
    Pietzcker A; Müller-Oerlinghausen B
    Pharmacopsychiatry; 1984 Sep; 17(5):162-7. PubMed ID: 6149570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Perazine in the treatment of psychotic disorders--research review].
    Kiejna A
    Psychiatr Pol; 2010; 44(3):427-34. PubMed ID: 20672521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orthostatic challenge during neuroleptic test dose: a possible predictor of short-term outcome.
    Volz HP; Mackert A; Diefenbacher A; Friedrich A; Gaebel W; Müller H; Stock G; Möller HJ
    Neuropsychobiology; 1994; 30(2-3):94-100. PubMed ID: 7800170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding of perazine to alpha 1-acid glycoprotein.
    Schley J; Siegert M; Müller-Oerlinghausen B
    Eur J Clin Pharmacol; 1980 Nov; 18(6):501-4. PubMed ID: 6109633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Residual symptoms and P300 in schizophrenic outpatients.
    Juckel G; Müller-Schubert A; Gaebel W; Hegerl U
    Psychiatry Res; 1996 Nov; 65(1):23-32. PubMed ID: 8953658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No correlation between neuroleptic-induced increase of beta-endorphin serum level and therapeutic efficacy in schizophrenia.
    Naber D; Nedopil N; Eben E
    Br J Psychiatry; 1984 Jun; 144():651-3. PubMed ID: 6146374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of neuroleptic on-drug response in schizophrenic in-patients by EEG.
    Ulrich G; Gaebel W; Pietzcker A; Müller-Oerlinghausen B; Stieglitz RD
    Eur Arch Psychiatry Neurol Sci; 1988; 237(3):144-55. PubMed ID: 2898366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.